The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 6, 2011, Pages 1400-1408

  Olivier, J D A ^a   Blom, T ^a   Arentsen, T ^a   Homberg, J R ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Adolescent; Anxiety; Depression; Development; Epigenetics; Selective serotonin reuptake inhibitor

Indexed keywords

FLUOXETINE; SEROTONIN;

ABNORMAL BEHAVIOR; AGE DISTRIBUTION; AGGRESSION; AGITATION; ANXIETY DISORDER; AUTISM; BEHAVIORAL SCIENCE; BRAIN SIZE; CARDIOVASCULAR DISEASE; CHILD HEALTH; COMPULSION; DEPRESSION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; EPIGENETICS; EVIDENCE BASED MEDICINE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LOCOMOTION; LOW BIRTH WEIGHT; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NONREM SLEEP; OUTCOME ASSESSMENT; PREMATURITY; PRENATAL DRUG EXPOSURE; PULMONARY HYPERTENSION; REM SLEEP; RISK ASSESSMENT; SEROTONINERGIC NERVE; SEROTONINERGIC TRANSMISSION; SEXUAL BEHAVIOR; SHORT SURVEY; SIDE EFFECT; SOCIAL BEHAVIOR; SOCIAL LEARNING; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TERATOGENICITY; TERATOLOGY;

AGE FACTORS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; FLUOXETINE; HUMANS; NEURONAL PLASTICITY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 79960439151     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.09.013     Document Type: Short Survey

References (142)

1. Alexandre C., Popa D., Fabre V., Bouali S., Venault P., Lesch K.P., et al. Early life blockade of 5-hydroxytryptamine 1A receptors normalizes sleep and depression-like behavior in adult knock-out mice lacking the serotonin transporter. J Neurosci 2006, 26:5554-64.
2. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-499.
3. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-81.
4. Asberg M., Thoren P., Traskman L., Bertilsson L., Ringberger V. "Serotonin depression" - a biochemical subgroup within the affective disorders?. Science 1976, 191:478-480.
5. Bairy K.L., Madhyastha S., Ashok K.P., Bairy I., Malini S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007, 79:1-11.
6. Bannister A.J., Kouzarides T. Reversing histone methylation. Nature 2005, 436:1103-1106.
7. Bar-Oz B., Einarson T., Einarson A., Boskovic R., O'Brien L., Malm H., et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007, 29:918-26.
8. Beltz B.S., Benton J.L., Sullivan J.M. Transient uptake of serotonin by newborn olfactory projection neurons. Proc Natl Acad Sci USA 2001, 98:12730-12735.
9. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999, 19:10494-501.
10. Bennett H.A., Einarson A., Taddio A., Koren G., Einarson T.R. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103:698-709.
11. Bhansali P., Dunning J., Singer S.E., David L., Schmauss C. Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q. J Neurosci 2007, 27:1467-73.
12. Bhatia S.K., Bhatia S.C. Childhood and adolescent depression. Am Fam Physician 2007, 75:73.
13. Blazer D.G., Kessler R.C., McGonagle K.A., Swartz M.S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994, 151:979-86.
14. Bonari L., Pinto N., Ahn E., Einarson A., Steiner M., Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004, 49:726-35.
15. Boylan C.B., Blue M.E., Hohmann C.F. Modeling early cortical serotonergic deficits in autism. Behav Brain Res 2007, 176:94-108.
16. Buhot M.C. Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 1997, 7:243-254.
17. Buhot M.C., Martin S., Segu L. Role of serotonin in memory impairment. Ann Med 2000, 32:210-221.
18. Cabrera T.M., Battaglia G. Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 1994, 269:637-45.
19. Carrillo M., Ricci L.A., Coppersmith G.A., Melloni R.H. The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies. Psychopharmacology (Berl) 2009, 205:349-68.
20. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408.
21. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
22. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-87.
23. Chan J.S., Olivier B., de Jong T.R., Snoeren E.M., Kooijman E., van Hasselt F.N., et al. Translational research into sexual disorders: pharmacology and genomics. Eur J Pharmacol 2008, 585:426-435.
24. Chung T.K., Lau T.K., Yip A.S., Chiu H.F., Lee D.T. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001, 63:830-834.
25. Cipriani A., Brambilla P., Furukawa T., Geddes J., Gregis M., Hotopf M., et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005, 4:CD004185.
26. Cowen D.S., Takase L.F., Fornal C.A., Jacobs B.L. Age-dependent decline in hippocampal neurogenesis is not altered by chronic treatment with fluoxetine. Brain Res 2008, 1228:14-19.
27. Crowley J.J., Brodkin E.S., Blendy J.A., Berrettini W.H., Lucki I. Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 2006, 31:2433-42.
28. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
29. Datla K.P., Mitra S.K., Bhattacharya S.K. Serotonergic modulation of footshock induced aggression in paired rats. Indian J Exp Biol 1991, 29:631-635.
30. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62:479-93.
31. de Jong T.R., Veening J.G., Waldinger M.D., Cools A.R., Olivier B. Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev 2006, 30:893-907.
32. Dugovic C., Solberg L.C., Redei E., Van R.O., Turek F.W. Sleep in the Wistar-Kyoto rat, a putative genetic animal model for depression. NeuroReport 2000, 11:627-31.
33. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
34. Evans J., Heron J., Francomb H., Oke S., Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001, 323:257-260.
35. Ferrari P.F., Palanza P., Parmigiani S., de Almeida R.M., Miczek K.A. Serotonin and aggressive behavior in rodents and nonhuman primates: predispositions and plasticity. Eur J Pharmacol 2005, 526:259-273.
36. Field T. Prenatal depression and selective serotonin reuptake inhibitors. Int J Neurosci 2010, 120:163-167.
37. Field T., Diego M., Hernandez-Reif M. Prenatal depression effects and interventions: a review. Infant Behav Dev 2010, May 12 Epub ahead of print.
38. Forcelli P.A., Heinrichs S.C. Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict Biol 2008, 13:52-62.
39. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003, 4:1002-12.
40. Gentile S., Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011, 128:1-9.
41. Gibbons R.D., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., Erkens J.A., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007, 164:1356-63.
42. Gingrich J.A., Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl) 2001, 155:1-10.
43. Gomes K.S., Nunes-De-Souza R.L. Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1261-1269.
44. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002, 36:1577-1589.
45. Griebel G., Cohen C., Perrault G., Sanger D.J. Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol Behav 1999, 67:315-320.
46. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400.
47. Guirado R., Varea E., Castillo-Gomez E., Gomez-Climent M.A., Rovira-Esteban L., Blasco-Ibanez J.M., et al. Effects of chronic fluoxetine treatment on the rat somatosensory cortex: activation and induction of neuronal structural plasticity. Neurosci Lett 2009, 457:12-15.
48. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63:332-339.
49. Hansen H.H., Mikkelsen J.D. Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 1998, 352:307-15.
50. Hansen H.H., Sanchez C., Meier E. Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression?. J Pharmacol Exp Ther 1997, 283:1333-41.
51. Heninger G.R. Indoleamines: the role of serotonin in clinical disorders. Psychopharmacology: the fourth generation of progress 2005, 471-482. Raven Press, New York. F.E. Bloom, D.J. Kupker (Eds.).
52. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003, 72:1665-82.
53. Hodes G.E., Yang L., Van K.J., Santollo J., Shors T.J. Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex. Neuroscience 2009, 163:609-617.
54. Homberg J.R., Schubert D., Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010, 31:60-65.
55. Huang G.J., Bannerman D., Flint J. Chronic fluoxetine treatment alters behavior, but not adult hippocampal neurogenesis, in BALB/cJ mice. Mol Psychiatry 2008, 13:119-21.
56. Iniguez S.D., Warren B.L., Bolanos-Guzman C.A. Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats. Biol Psychiatry 2010, 67:1057-66.
57. Ipser J.C., Stein D.J., Hawkridge S., Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009, (3):CD005170.
58. Ivarsson M., Paterson L.M., Hutson P.H. Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. Eur J Pharmacol 2005, 522:63-71.
59. Janusonis S., Gluncic V., Rakic P. Early serotonergic projections to Cajal - Retzius cells: relevance for cortical development. J Neurosci 2004, 24:1652-1659.
60. Josefsson A., Berg G., Nordin C., Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001, 80:251-255.
61. Karpova N.N., Lindholm J., Pruunsild P., Timmusk T., Castren E. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009, 19:97-108.
62. Kim J., Riggs K.W., Misri S., Kent N., Oberlander T.F., Grunau R.E., et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006, 61:155-63.
63. Kinnally E.L., Capitanio J.P., Leibel R., Deng L., Leduc C., Haghighi F., et al. Epigenetic regulation of serotonin transporter expression and behavior in infant rhesus macaques. Genes Brain Behav 2010, 9:575-582.
64. Kobayashi K., Ikeda Y., Sakai A., Yamasaki N., Haneda E., Miyakawa T., et al. Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 2010, 107:8434-8439.
65. Kostowski W., Valzelli L., Kozak W., Bernasconi S. Activity of desipramine, fluoxetine and nomifensine on spontaneous and p-CPA-induced muricidal aggression. Pharmacol Res Commun 1984, 16:265-71.
66. Kriegebaum C., Gutknecht L., Schmitt A., Lesch K.P., Reif A. Serotonin now: part 1. Fortschr Neurol Psychiatr 2010, 78(6):319-31.
67. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
68. Kristensen J.H., Ilett K.F., Hackett L.P., Yapp P., Paech M., Begg E.J. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999, 48:521-27.
69. Laine K., Heikkinen T., Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60:720-726.
70. LaRoche R.B., Morgan R.E. Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats. Neurotoxicol Teratol 2007, 29:96-107.
71. Lebrand C., Cases O., Adelbrecht C., Doye A., Alvarez C., el M.S., et al. Transient uptake and storage of serotonin in developing thalamic neurons. Neuron 1996, 17:823-835.
72. Lee L.J. Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009, 15:212-223.
73. Lisboa S.F., Oliveira P.E., Costa L.C., Venancio E.J., Moreira E.G. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007, 80:49-56.
74. Lovrin M. Treatment of major depression in adolescents: weighing the evidence of risk and benefit in light of black box warnings. J Child Adolesc Psychiatr Nurs 2009, 22:63-68.
75. Luhmann H.J., Hanganu I., Kilb W. Cellular physiology of the neonatal rat cerebral cortex. Brain Res Bull 2003, 60:345-53.
76. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009, 10:434-445.
77. Ma J., Lee K.V., Stafford R.S. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005, 37:434-42.
78. Maciag D., Simpson K.L., Coppinger D., Lu Y., Wang Y., Lin R.C., et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006, 31:47-57.
79. Manhães de Castro R., Barreto Medeiros J.M., Mendes D.S., Ferreira L.M., Guedes R.C., Cabral Filho J.E., et al. Reduction of intraspecific aggression in adult rats by neonatal treatment with a selective serotonin reuptake inhibitor. Braz J Med Biol Res 2001, 34:121-124.
80. March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
81. Marcussen A.B., Flagstad P., Kristjansen P.E., Johansen F.F., Englund U. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand 2008, 117:94-100.
82. Masi G., Liboni F., Brovedani P. Pharmacotherapy of major depressive disorder in adolescents. Expert Opin Pharmacother 2010, 11:375-386.
83. Maswood N., Sarkar J., Uphouse L. Modest effects of repeated fluoxetine on estrous cyclicity and sexual behavior in Sprague Dawley female rats. Brain Res 2008, 1245:52-60.
84. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev 1999, 23:1111-1125.
85. Miller C.A., Gavin C.F., White J.A., Parrish R.R., Honasoge A., Yancey C.R., et al. Cortical DNA methylation maintains remote memory. Nat Neurosci 2010, 13:664-666.
86. Mirmiran M., van de Poll N.E., Corner M.A., van Oyen H.G., Bour H.L. Suppression of active sleep by chronic treatment with chlorimipramine during early postnatal development: effects upon adult sleep and behavior in the rat. Brain Res 1981, 204:129-46.
87. Molteni R., Cattaneo A., Calabrese F., Macchi F., Olivier J.D., Racagni G., et al. Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiol Dis 2010, 37:747-55.
88. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005, 293:2372-2383.
89. Narboux-Nême N., Pavone L.M., Avallone L., Zhuang X., Gaspar P. Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology 2008, 55:994-105.
90. Navailles S., Hof P.R., Schmauss C. Antidepressant drug-induced stimulation of mouse hippocampal neurogenesis is age-dependent and altered by early life stress. J Comp Neurol 2008, 509:372-81.
91. Nonacs R.M., Soares C.N., Viguera A.C., Pearson K., Poitras J.R., Cohen L.S. Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol 2005, 8:445-449.
92. Noorlander C.W., Ververs F.F., Nikkels P.G., van Echteld C.J., Visser G.H., Smidt M.P. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008, 3:e2782.
93. Norcross M., Mathur P., Enoch A.J., Karlsson R.M., Brigman J.L., Cameron H.A., et al. Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharmacology (Berl) 2008, 200:413-424.
94. Oberlander T.F., Grunau R.E., Fitzgerald C., Papsdorf M., Rurak D., Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005, 115:411-425.
95. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63:898-906.
96. Oberlander T.F., Reebye P., Misri S., Papsdorf M., Kim J., Grunau R.E. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007, 161:22-29.
97. Oberlander T.F., Bonaguro R.J., Misri S., Papsdorf M., Ross C.J., Simpson E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008, 13:65-73.
98. Oberlander T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008, 84:689-97.
99. Oberlander T.F., Papsdorf M., Brain U.M., Misri S., Ross C., Grunau R.E. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3years of age. Arch Pediatr Adolesc Med 2010, 164:444-451.
100. Ogawa M., Miyata T., Nakajima K., Yagyu K., Seike M., Ikenaka K., et al. The reeler gene-associated antigen on Cajal - Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron 1995, 14:899-912.
101. Oh J.E., Zupan B., Gross S., Toth M. Paradoxical anxiogenic response of juvenile mice to fluoxetine. Neuropsychopharmacology 2009, 34:2197-2207.
102. Olfson M., Marcus S.C., Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006, 63:865-72.
103. Pare W.P., Kluczynski J. Differences in the stress response of Wistar-Kyoto (WKY) rats from different vendors. Physiol Behav 1997, 62:643-648.
104. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., gis-Balboa R.C., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328:753-756.
105. Persico A.M., Mengual E., Moessner R., Hall F.S., Revay R.S., Sora I., et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci 2001, 21:6862-6873.
106. Poltronieri S.C., Zangrossi H., de Barros V. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 2003, 147:185-92.
107. Popa D., Lena C., Alexandre C., Adrien J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 2008, 28:3546-54.
108. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Thér 1977, 229:327-36.
109. Rampono J., Proud S., Hackett L.P., Kristensen J.H., Ilett K.F. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol 2004, 7:329-34.
110. Renthal W., Nestler E.J. Chromatin regulation in drug addiction and depression. Dialogues Clin Neurosci 2009, 11:257-268.
111. Riedel W.J., Klaassen T., Deutz N.E., van S.A., van Praag H.M. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999, 141:362-369.
112. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
113. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005, 365:482-487.
114. Schmitt J.A., Jorissen B.L., Sobczak S., van Boxtel M.P., Hogervorst E., Deutz N.E., et al. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol 2000, 14:21-29.
115. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12:247-57.
116. Silber B.Y., Schmitt J.A. Effects of tryptophan loading on human cognition, mood, and sleep. Neurosci Biobehav Rev 2010, 34:387-407.
117. Stahl S.M. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. J Clin Psychiatry 1997, 58(Suppl 8):20-26.
118. Svenningsson P., Tzavara E.T., Qi H., Carruthers R., Witkin J.M., Nomikos G.G., et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci 2007, 27:4201-4209.
119. Tecott L.H. Serotonin and the orchestration of energy balance. Cell Metab 2007, 6:352-361.
120. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999, 60(Suppl 17):28-31.
121. Tissot R. The common pathophysiology of monaminergic psychoses: a new hypothesis. Neuropsychobiology 1975, 1:243-260.
122. Trivedi M.H., Rush A.J., Armitage R., Gullion C.M., Grannemann B.D., Orsulak P.J., et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999, 20:447-459.
123. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-25.
124. Uphouse L., Hensler J.G., Sarkar J., Grossie B. Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats. Brain Res 2006, 1072:79-90.
125. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2008, 18:62-73.
126. van den Hove D.L., Blanco C.E., Scheepens A., Desbonnet L., Myint A.M., Leonard B.E., et al. Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary study. Neonatology 2008, 93:52-55.
127. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:85-102.
128. Ververs T., Kaasenbrood H., Visser G., Schobben F., de Jong-van den Berg, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006, 62:863-870.
129. Vidal R., Valdizan E.M., Mostany R., Pazos A., Castro E. Long-term treatment with fluoxetine induces desensitization of 5-HT4 receptor-dependent signalling and functionality in rat brain. J Neurochem 2009, 110:1120-1127.
130. Vitalis T., Cases O., Callebert J., Launay J.M., Price D.J., Seif I., et al. Effects of monoamine oxidase A inhibition on barrel formation in the mouse somatosensory cortex: determination of a sensitive developmental period. J Comp Neurol 1998, 393:169-84.
131. Vogel G., Neill D., Hagler M., Kors D. A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 1990, 14:85-91.
132. Vorhees C.V., cuff-Smith K.D., Schilling M.A., Fisher J.E., Moran M.S., Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994, 23:194-205.
133. Wagner G.C., Fisher H., Pole N., Borve T., Johnson S.K. Effects of monoaminergic agonists on alcohol-induced increases in mouse aggression. J Stud Alcohol 1993, (Suppl 11):185-91.
134. Walsh M.T., Dinan T.G. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand 2001, 104:84-91.
135. Wang J.W., David D.J., Monckton J.E., Battaglia F., Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008, 28:1374-84.
136. Wei F., Dubner R., Zou S., Ren K., Bai G., Wei D., et al. Molecular depletion of descending serotonin unmasks its novel facilitatory role in the development of persistent pain. J Neurosci 2010, 30:8624-8636.
137. Whitaker-Azmitia P.M. Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001, 56:479-85.
138. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004, 363:1341-1345.
139. Wilens T.E., Biederman J., Kwon A., Chase R., Greenberg L., Mick E., et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003, 13:143-152.
140. Wilkinson M.B., Xiao G., Kumar A., LaPlant Q., Renthal W., Sikder D., et al. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009, 29:7820-7832.
141. Xu Y., Sari Y., Zhou F.C. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res 2004, 150:151-61.
142. Zito J.M., Safer D.J., DosReis S., Gardner J.F., Soeken K., Boles M., et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002, 109:721-727.